|Articles|December 1, 2000

December 2000
Volume 6
Issue 12

Drugs and the Elderly, Part 1: The Problems Facing Managed Care

Author(s)Mark H. Beers, MD, Robert W. Baran, PharmD, Kathleen Frenia, PharmD

Download PDF: Drugs and the Elderly, Part 1: The Problems Facing Managed Care

Articles in this issue

over 25 years ago

Article

Impact of Birthweight on Healthcare Charges Within a Managed Care Organization

over 25 years ago

Article

Patient Preferences for Laboratory Test Results Notification

over 25 years ago

Article

Surviving the Prospective Payment System: Potential Problems and Solutions to Ensure Quality of Care

over 25 years ago

Article

Determinants of Antidepressant Treatment Outcome

over 25 years ago

Article

The Role of Health Literacy in Narrowing the Treatment Gap for Hypercholesterolemia

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Drugs and the Elderly, Part 1: The Problems Facing Managed Care

Articles in this issue

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

ACA Enrollment Erosion Deepens After Open Enrollment Ends

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Shields Health Solutions Partners With Baptist Health on Specialty Pharmacy

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD